Developing differentiated, best-in-class mAbs for immune-mediated diseases

Maximizing the power of mAbs

At Climb, we are focused on developing monoclonal antibodies that are optimized to meet the needs of patients living with serious, immune-mediated diseases. Our product candidates are crafted with intelligent designs that yield strong efficacy, excellent tolerability, and the flexibility to support extended dosing intervals that are customized per indication.

• Focused on clinically validated B cell targets that have broad potential to provide the safe, effective, and durable knockdown of pathogenic cycles
• Developing assets with high specificity and potency in mAb formats that are engineered for extended therapeutic windows
• Exploring dose level and frequency to find the best solution for treating a wide variety of immune-mediated diseases